Results 211 to 220 of about 5,052,436 (221)

Thrombolytic therapies for ischemic stroke: Triumphs and future challenges.

Neuropharmacology, 2018
A. Moussaddy, A. Demchuk, M. Hill
semanticscholar   +1 more source

Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

American Journal of Cardiology, 2017
Sean T. Chen, A. Hellkamp, R. Becker, S. Berkowitz, G. Breithardt, K. Fox, W. Hacke, J. Halperin, G. Hankey, K. Mahaffey, Christopher C. Nessel, J. Piccini, D. Singer, M. Patel   +13 more
semanticscholar   +1 more source

Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents

Journal of Thrombosis and Thrombolysis, 2001

exaly  

Biological Standards for Potency Assignment to Fibrinolytic Agents Used in Thrombolytic Therapy

Seminars in Thrombosis and Hemostasis, 2014
Craig Thelwell
exaly  

Translational initiatives in thrombolytic therapy

Frontiers in Medicine, 2017
M. Klegerman
semanticscholar   +1 more source

Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial

Lancet, The, 2000
Kim Fox, Wiek H van Gilst
exaly  

Guidelines for the Use of Thrombolytic Agents

New England Journal of Medicine, 1979
W R Bell, William R Bell
exaly  

Antithrombin Agents as Adjuncts to Thrombolytic Therapy

Journal of Thrombosis and Thrombolysis, 1999
Harvey D White, John French
exaly  

Therapeutic use of thrombolytic agents

American Journal of Hospital Pharmacy, 1981
exaly  

Efficacy, Safety, and Cost of Thrombolytic Agents for the Management of Dysfunctional Hemodialysis Catheters: A Systematic Review

Pharmacotherapy, 2011
exaly